GGrantIndex
← Leaderboards

Kathleen Colleran

University Of New Mexico

$1,079,678
Attributed
$1,079,678
Total exposure
18
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $142.4K · FY200510
$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10

Funding mix

By agency

NIH$1,079,678 · 18

By mechanism

M01$1,079,678 · 18

Top collaborators

No co-investigators on record.

Most similar at University Of New Mexico

Same institution · by research overlap

Others in their field

Top investigators on “Grant

Research focus

GrantResearch PersonnelResourcesInstitutionSourceFundingComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthClinical ResearchHomocysteineHuman SubjectOxidative StressBiomarkerDisease /Disorder EtiologyAtorvastatinPharmaceutical PreparationsPlasminogen Activator Inhibitor 1InflammationHyperthyroidismHydrochlorothiazideResponseAmlodipineBlood PressureFolate Deficiency

Grant awards (23)

THE PLEIOTROPIC EFFECTS OF ATORVASTATIN WHEN COMBINED WITH$21,156
M01 · FY2010 · RR · contact PI
DECREASED PULMONARY FUNCTION, YET ANOTHER RAMIFICATION OF CHILDHOOD$255
M01 · FY2010 · RR · contact PI
THE PLEIOTROPIC EFFECTS OF ATORVASTATIN WHEN COMBINED WITH$16,516
M01 · FY2009 · RR · contact PI
HEALTH OUTCOMES ASSOCIATED WITH THE INTRODUCTION OF A MULTIDISCIPLINARY$13,083
M01 · FY2008 · RR · contact PI
CARVEDILOL VS METOPOLOL: A COMPARISON OF ENDOTHELIAL FUNCTION$6,784
M01 · FY2008 · RR · contact PI
THE PLEIOTROPIC EFFECTS OF ATORVASTATIN WHEN COMBINED WITH$484
M01 · FY2008 · RR · contact PI
CARVEDILOL VS METOPOLOL: A COMPARISON OF ENDOTHELIAL FUNCTION$63,090
M01 · FY2007 · RR · contact PI
THE PLEIOTROPIC EFFECTS OF ATORVASTATIN WHEN COMBINED WITH$42,995
M01 · FY2007 · RR · contact PI
THE ROLE OF PAI-1 AND ADIPOSE METABOLIC ACTIVITY IN THE CARDIOPROTECTION$5,608
M01 · FY2007 · RR · contact PI
HEALTH OUTCOMES ASSOCIATED WITH THE INTRODUCTION OF A MULTIDISCIPLINARY$5,608
M01 · FY2007 · RR · contact PI
CARVEDILOL VS METOPOLOL: A COMPARISON OF ENDOTHELIAL FUNCTION$100,203
M01 · FY2006 · RR · contact PI
THE ROLE OF PAI-1 AND ADIPOSE METABOLIC ACTIVITY IN THE CARDIOPROTECTION$35,256
M01 · FY2006 · RR · contact PI
THE PLEIOTROPIC EFFECTS OF ATORVASTATIN WHEN COMBINED WITH$5,103
M01 · FY2006 · RR · contact PI
HEALTH OUTCOMES ASSOCIATED WITH THE INTRODUCTION OF A MULTIDISCIPLINARY$1,855
M01 · FY2006 · RR · contact PI
THE ROLE OF PAI-1 AND ADIPOSE METABOLIC ACTIVITY IN THE CARDIOPROTECTION$82,392
M01 · FY2005 · RR
HEALTH OUTCOMES ASSOCIATED WITH THE INTRODUCTION OF A MULTIDISCIPLINARY$38,413
M01 · FY2005 · RR
CARVEDILOL VS METROPOLOL: A COMPARISON OF EFFECTS ON ENDOTHELIAL$3,340
M01 · FY2005 · RR
Health Outcomes of CHD$26,816
M01 · FY2004 · RR
Carvedilol vs. Metropolol: Effects on Endothelial$23,464
M01 · FY2004 · RR
THYROTOXICOSIS MAY BE ASSOCIATED W/ VITAMIN B &FOLATE DEFICIENCIES$282,412
M01 · FY2002 · RR
THYROTOXICOSIS MAY BE ASSOCIATED W/ VITAMIN B &FOLATE DEFICIENCIES$282,412
M01 · FY2001 · RR
THYROTOXICOSIS MAY BE ASSOCIATED W/ VITAMIN B &FOLATE DEFICIENCIES$22,433
M01 · FY2000 · RR
THYROTOXICOSIS MAY BE ASSOCIATED W/ VITAMIN B &FOLATE DEFICIENCIES$0
M01 · FY2000 · RR